Dose-related effects of dexamethasone on liver damage due to bile duct ligation in rats

Basit Öğe Kaydı
dc.contributor.authorEken, Halil
dc.contributor.authorOzturk, Hayrettin
dc.contributor.authorOzturk, Hulya
dc.contributor.authorBuyukbayram, Huseyin
dc.date.accessioned2024-04-24T17:20:56Z
dc.date.available2024-04-24T17:20:56Z
dc.date.issued2006
dc.departmentDicle Üniversitesien_US
dc.description.abstractAIM: To evaluate the effects of dexamethasone on liver damage in rats with bile duct ligation. METHODS: A total of 40 male Sprague-Dawley rats, weighing 165-205 g, were used in this study. Group 1 (sham-control, n = 10) rats underwent laparotomy alone and the bile duct,was just dissected from the surrounding tissue. Group 2 rats (untreated, n = 10) were subjected to bile duct ligation (BDL) and no drug was applied. Group 3 rats (low-dose dexa, n = 10) received a daily dose of dexamethasone by orogastric tube for 14 d after BDL. Group 4 rats (high-dose dexa, n = 10) received a daily dose of dexamethasone by orogastric tube for 14 d after BDL. At the end of the two-week period, biochemical and histological evaluations were processed. RESULTS: The mean serum bilirubin and liver enzyme levels significantly decreased, and superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GSH-Px) values were significantly increased in low-dose dexa and high-dose dexa groups when compared to the untreated group. The histopathological score was significantly less in the low-close and high-dose dexa groups compared to the untreated rats. In the low-dose dexa group, moderate liver damage was seen, while mild liver damage was observed in the high-dose dexa group. CONCLUSION: Corticosteroids reduced liver damage produced by bile duct obstruction. However, the histopathological score was not significantly lower in the high-dose corticosteroid group as compared to the low-dose group. Thus, low-dose corticosteroid provides a significant reduction of liver damage without increased side effects, while high dose is associated not with lower fibrosis but with increased side effects. (c) 2006 The WJG Press. All rights reserved.en_US
dc.identifier.doi10.3748/wjg.v12.i33.5379
dc.identifier.endpage5383en_US
dc.identifier.issn1007-9327
dc.identifier.issn2219-2840
dc.identifier.issue33en_US
dc.identifier.pmid16981272
dc.identifier.scopus2-s2.0-33749389903
dc.identifier.scopusqualityQ1
dc.identifier.startpage5379en_US
dc.identifier.urihttps://doi.org/10.3748/wjg.v12.i33.5379
dc.identifier.urihttps://hdl.handle.net/11468/19308
dc.identifier.volume12en_US
dc.identifier.wosWOS:000240646900020
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherBaishideng Publishing Group Incen_US
dc.relation.ispartofWorld Journal of Gastroenterology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBile Duct Ligationen_US
dc.subjectHepatic Fibrosisen_US
dc.subjectDexamethasoneen_US
dc.titleDose-related effects of dexamethasone on liver damage due to bile duct ligation in ratsen_US
dc.titleDose-related effects of dexamethasone on liver damage due to bile duct ligation in rats
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu